GSA Capital Partners’s Vir Biotechnology VIR Stock Holding History

GSA Capital Partners’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-76,416	Closed	-$685K	–	2197
2026 Q1	$685K	Buy	76,416 +51,475	+206%	+$410K	0.04%	723
2025 Q4	$150K	Buy	24,941 +10,195	+69%	+$60.7K	0.01%	1477
2025 Q3	$84K	Sell	14,746 -53,062	-78%	-$271K	0.01%	1540
2025 Q2	$342K	Buy	67,808 +49,409	+269%	+$265K	0.02%	1178
2025 Q1	$119K	Buy	+18,399	New	+$164K	0.01%	1476
2023 Q4	–	Sell	-117,131	Closed	-$1.1M	–	1963
2023 Q3	$1.1M	Buy	+117,131	New	+$1.67M	0.09%	347
2022 Q1	–	Sell	-13,925	Closed	-$583K	–	1865
2021 Q4	$583K	Sell	13,925 -14,608	-51%	-$572K	0.07%	507
2021 Q3	$1.24M	Buy	28,533 +23,032	+419%	+$997K	0.13%	204
2021 Q2	$260K	Buy	+5,501	New	+$250K	0.03%	1033

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GSA Capital Partners's VIR Position: Q2 2026 in Review

GSA Capital Partners sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 76,416 shares — an estimated $685K sold.

GSA Capital Partners first reported a position in VIR in Q2 2021 and held it in 9 quarters. The position peaked at $1.24M in Q3 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

GSA Capital Partners reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
GSA Capital Partners sold 76,416 Vir Biotechnology shares in Q2 2026, an estimated $685K.
GSA Capital Partners first reported a position in Vir Biotechnology in Q2 2021 and held it in 9 quarters.
GSA Capital Partners's Vir Biotechnology position peaked at $1.24M in Q3 2021.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.